Vela Technologies #VELA – Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases July 17, 2024 – Posted in: Vela Technologies Plc (VELA)

Read here Conduit Pharmaceuticals Inc. (Nasdaq: CDT) today announced the approval of a composition of matter patent application by IP Australia, achieving successful examination of a patent on its lead asset, an HK-4 Glucokinase Activator which targets a wide range of autoimmune diseases. The Company is enrolled to participate in the Patent Prosecution Highway (PPH), a program to fast-track patent examination in major jurisdictions including the U.S., Europe and Japan. Since IP Australia has allowed…

Continue reading